ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Renal Impairment on the Pharmacokinetics of NN9535

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00833716
Recruitment Status : Completed
First Posted : February 2, 2009
Last Update Posted : April 4, 2017
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 26, 2010
  Actual Study Completion Date : July 26, 2010
Publications of Results:
Marbury T, Flint A, Segel S, Lindegaard M, Lasseter K. Pharmacokinetics and tolerability of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment. Diabetes 2014; 63 (Suppl 1): A260 (abstract 1010-P)